Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Principal researcher/writer at Which? delivering award-winning health, baby and safety investigations, including our annual sunscreen tests. Cybex car seats can be confusing, as many have very similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback